Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells 558 Shares of Stock

Key Points

• Director Ezra Friedberg sold 558 shares of Pelthos Therapeutics at an average price of $20.72, generating $11,561.76. The sale occurred under a pre-arranged Rule 10b5-1 trading plan and reduced his ownership by 0.69%.
• Pelthos shares rose 4.8% to $21.48, but the clinical-stage biotech remains unprofitable, reporting a quarterly loss of $6.62 per share and $15.6 million in revenue. Analysts expect a full-year loss of $15.22 per share.
• Institutional investors own nearly 78% of the company, while analysts maintain a “Moderate Buy” consensus rating with a $55.40 average price target, despite Oppenheimer lowering its target to $64.

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Ezra Friedberg sold 558 shares of the firm's stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $20.72, for a total value of $11,561.76. Following the transaction, the director directly owned 80,484 shares of the company's stock, valued at approximately $1,667,628.48. This represents a 0.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 4.8%

Shares of NYSEAMERICAN PTHS traded up $0.98 during trading on Tuesday, reaching $21.48. The company had a trading volume of 42,943 shares, compared to its average volume of 30,248. The stock has a market cap of $82.27 million, a P/E ratio of -0.98 and a beta of 3.07. The company's fifty day moving average price is $24.74 and its 200-day moving average price is $25.21. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics Inc. has a 12 month low of $18.19 and a 12 month high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) earnings per share (EPS) for the quarter. The company had revenue of $15.60 million for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. As a group, research analysts expect that Pelthos Therapeutics Inc. will post -15.22 earnings per share for the current year.

Institutional Investors Weigh In On Pelthos Therapeutics

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr boosted its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Free Report) by 9.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,073 shares of the company's stock after purchasing an additional 1,792 shares during the quarter. Knott David M Jr owned about 0.63% of Pelthos Therapeutics worth $443,000 at the end of the most recent quarter. Institutional investors own 77.96% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer dropped their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an "outperform" rating on the stock in a research report on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $55.40.

About Pelthos Therapeutics

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company's work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company's specific product pipeline, operating history, geographic reach and leadership is limited.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.